The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Dr. Amy Heimberger on Immunotherapeutics in the Context of Glioblastoma

Amy Heimburger, MD
Published Online: 3:11 PM, Mon November 23, 2015


Amy Heimberger, MD, professor in the Department of Neurosurgery, University of Texas MD Anderson Cancer Center, talks about immunotheraputics in the context of glioblastoma (GBM). Heimberger says the mechanisms that glioblastoma tumors use for suppression are much more heterogenous than other tumors. She said because of this, oncologists are now studying the effects of targeted the key hubs of tumor-mediated immune suppression.


Heimberger says one target of interest for oncologists is in the secreted protein FGL2. FGL2 is secreted by GBM and regulated several mechanisms of immune suppression. Heimberger says that by targeting FGL2, treatment could be more significant for GBM patients.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.